According to a press release issued by the White House in late May, President Trump expects drug manufacturers to commit to “aligning the prices of branded products” with the “lowest price of a set of economic peer countries.” The so-called most favored nation target price is the lowest in an Organization for Economic Cooperation and Development country with a Gross Domestic Product per capita of at least 60% of the United States. The memorandum, however, provides no details on actual price targets. These will likely prove difficult to calculate for a variety of reasons, including differences in timing of approval and pricing of pharmaceutical products by the respective regulatory authorities, as well as disparities in dosing and formulation. The document also doesn’t disclose how, throu

See Full Page